{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-015725","form_type":"8-K","ticker":"GTBP","cik":"0000109657","company_name":"GT Biopharma, Inc.","filed_at":"2025-09-26T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.332720+00:00","generated_at":"2026-05-17T05:31:28.180701+00:00","sec_items":["3.03","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"GT Biopharma Series L Preferred holders waive redemption rights – all holders now in agreement","bullets":["All Series L 10% Convertible Preferred Stock holders have waived redemption rights under Section 10 of the Certificate of Designations.","Additional holder provided waiver on September 25, 2025, completing the agreement across all holders.","Waiver eliminates potential redemption trigger that could require cash outlay, improving liquidity.","No financial impact disclosed; modification alters preferred stockholder rights."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-015725","json":"https://secwatch.observer/filing/0001493152-25-015725.json","markdown":"https://secwatch.observer/filing/0001493152-25-015725.md","text":"https://secwatch.observer/filing/0001493152-25-015725.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/109657/000149315225015725/0001493152-25-015725-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/109657/000149315225015725/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T05:31:28.180701+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}